CollPlant Biotechnologies Q2 Net Loss Narrows
(RTTNews) - CollPlant Biotechnologies Ltd(CLGN), a regenerative medicine and technology company, announced its second-quarter 2026 financial results, reflecting a narrower net loss.
For the three months ended June 30, 2026, net loss narrowed to $2.7 million, or $1.89 basic loss per share, from $3.3 million, or $2.83 per share in the prior year.
Adjusted net loss narrowed to $2.4 million, or $1.69 basic loss per share, from $2.7 million, or $2.30 basic loss per share, a year ago.
Revenue declined to $108,000 from $179,000 in the prior year, primarily attributed to lower sales of rhCollagen-based products.
As of June 30, 2026, cash and cash equivalents were $2.6 million.
The LightSolver acquisition was completed after the end of the quarter, and its results are not included in CollPlant's second-quarter financial results.
Through its subsidiary LightSolver, CollPlant is developing laser-based optical computing architectures for applications in artificial intelligence, aerospace, financial engineering and high-performance computing.
CLGN has traded between $2.64 and $26.80 over the last year. The stock closed Wednesday's trade at $3.78, down 0.53%.
For more such biotechstock news visit www.rttnews.com.
